{"id":"https://genegraph.clinicalgenome.org/r/1fcd4927-5557-4d07-84ba-4a1cba6d13f6v2.0","type":"EvidenceStrengthAssertion","dc:description":"*PTEN* gene encodes a phosphatidylinositol-3,4,5-trisphosphate 3 (PIP3)-phosphatase, which blocks phosphatidylinositol 3 kinase (PI3K) signaling by inhibiting PIP3 dependent processes such as the membrane recruitment and activation of AKT, therefore inhibiting cell survival, growth, and proliferation. In 1997, Steck et al. (PMID: 9090379) first identified *PTEN* gene and reported the association of germline PTEN variants with multiple cancer types, including breast cancer, kidney carcinoma and glioma. The PTEN hamartoma tumor syndrome (PHTS) includes Cowden syndrome (CS), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and PTEN-related Proteus-like syndrome. The phenotypes include macrocephaly, autism or developmental delay, intestinal hamartomatous polyposis, lipomas, pigmented macules of the glans penis, and a high risk for benign and malignant tumors of the thyroid, breast, kidney, and endometrium. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no difference in molecular mechanism(s) or inheritance pattern. Therefore, these phenotypes have been lumped into this curation. The mechanism of pathogenicity is reported to be loss of function.  Eight variants (nonsense, frameshift, and missense) that have been reported in 11 probands in 4 publications (PMIDs: 17526800, 22595938, 22628360, 36082652) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 Points) has been reached. This gene-disease relationship is also supported by experimental evidence, including in vitro functional assays and animal models (6 Points, PMIDs: 9356475, 9393738, 9778245, 21194675, 21343951, 21828076, 23066114). This experimental evidence demonstrates that PTEN is a protein phosphatase that exhibits functional and specific growth-suppressing activity. Additionally, heterozygous mutant mice demonstrate noticeable increased cell proliferation and significant macrocephaly as a result of megancephaly. A spectrum of immune phenotypes is associated with PTEN hamartoma tumor syndrome (PHTS), ranging from asymptomatic lymphopenia, to lymphoid hyperplasia, autoimmunity, and immunodeficiency (PMID: 31501268, 28523199, 26246517). While a majority of patients with PHTS do not present with immunodeficiency or immune dysregulation, many show evidence of subclinical immunological abnormalities such as reduced total numbers of CD4+ T cells, inverted CD4:CD8 ratio, or abnormal immunoglobulin subclasses (PMID: 31501268). The B cell phenotype is highly variable, with increased numbers of specific B cell subsets or increased immunoglobulin levels, in contrast to most antibody deficiencies where there is hypogammaglobulinemia and/or B cell deficiency. Autoimmune disorders, including Hashimoto's thyroiditis, celiac disease, autoimmune colitis, and autoimmune hemolytic anemia, have been reported in 29% of 79 PHTS patients in one study (PMID: 27477328). Mouse models of Pten loss-of-function recapitulate the patient immune phenotypes including hypergammaglobulinemia and autoimmunity (10497129) and impaired class-switch recombination and autoantibody production (PMID: 12615906). In summary, there is definitive evidence supporting the relationship between PTEN and autosomal dominant PTEN hamartoma tumor syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This gene-disease pair was originally evaluated as definitive by the PTEN GCEP on 10/09/2017. Secondary contributor evidence was provided by the PIRD GCEP. In summary, there is Definitive evidence to support this gene-disease relationship. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This re-curation as definitive was approved by the ClinGen Hereditary Cancer GCEP on 04/05/2024 (SOP Version 10).\n\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/1fcd4927-5557-4d07-84ba-4a1cba6d13f6","GCISnapshot":"https://genegraph.clinicalgenome.org/r/2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb","calculatedEvidenceStrength":"Definitive","changes":[{"id":"cg:otherTextChange"},{"id":"cg:newEvidence"},{"id":"cg:summaryChange"}],"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2025-09-29T16:36:33.137Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2024-04-05T17:00:00.000Z","role":"Approver"},{"agent":"https://genegraph.clinicalgenome.org/agent/10145","role":"SecondaryContributor"}],"curationReasons":["RecurationNewEvidence"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d946682-ddc2-4c6a-9702-d2a8dd8cb49b_proband_segregation","type":"FamilyCosegregation","dc:description":"Number of segregations less than required for consideration.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"9","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/5d946682-ddc2-4c6a-9702-d2a8dd8cb49b","type":"Family","rdfs:label":"9","member":{"id":"https://genegraph.clinicalgenome.org/r/0a95ea98-abae-400f-9df6-12a505833ef5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"9.1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":29,"allele":{"id":"https://genegraph.clinicalgenome.org/r/16eae146-5b54-48b9-ae56-f8962c0949aa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.510T>A (p.Ser170Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7815"}},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0012500","obo:HP_0008069","obo:HP_0001249","obo:HP_0000256"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/5e234865-4862-493e-92e9-4e3c291959e6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","allele":{"id":"https://genegraph.clinicalgenome.org/r/16eae146-5b54-48b9-ae56-f8962c0949aa"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0000256","obo:HP_0008069"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/0a95ea98-abae-400f-9df6-12a505833ef5"}},{"id":"https://genegraph.clinicalgenome.org/r/486aac1b-5f95-41fb-8f7c-5d8da2ec4e9a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22595938","rdfs:label":"559","family":{"id":"https://genegraph.clinicalgenome.org/r/486aac1b-5f95-41fb-8f7c-5d8da2ec4e9a","type":"Family","rdfs:label":"559","member":{"id":"https://genegraph.clinicalgenome.org/r/ee6f98a9-0370-4a51-970f-16cf8385a103","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22595938","rdfs:label":"559","ageType":"AgeAtReport","ageUnit":"Years","ageValue":40,"allele":{"id":"https://genegraph.clinicalgenome.org/r/be7206bb-99e4-4aea-b199-db7a841f6c8e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.389G>A (p.Arg130Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7829"}},"phenotypes":["obo:HP_0003002","obo:HP_0000256","obo:HP_0000853","obo:HP_0000131"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/267e5dff-6197-4982-a1f3-176d2074c5d5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22595938","allele":{"id":"https://genegraph.clinicalgenome.org/r/be7206bb-99e4-4aea-b199-db7a841f6c8e"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0003002","obo:HP_0000853","obo:HP_0000131","obo:HP_0000256"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/ee6f98a9-0370-4a51-970f-16cf8385a103"}},{"id":"https://genegraph.clinicalgenome.org/r/b31c5a3a-dcaf-42d8-9e07-bf2a20b65564_proband_segregation","type":"FamilyCosegregation","dc:description":"Number of segregations less than required for consideration.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"11","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/b31c5a3a-dcaf-42d8-9e07-bf2a20b65564","type":"Family","rdfs:label":"11","member":{"id":"https://genegraph.clinicalgenome.org/r/5b9113ec-aa38-4824-9a8b-6ac3d7c3a732","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"11.1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/cc598fa1-2639-4672-8797-1cec18628a77","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.800del (p.Lys267ArgfsTer9)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/92828"}},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000256","obo:HP_0031447","obo:HP_0001249"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/0fcd4e51-616e-43b6-9db1-cef478806eca_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","allele":{"id":"https://genegraph.clinicalgenome.org/r/cc598fa1-2639-4672-8797-1cec18628a77"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":"obo:HP_0000256","proband":{"id":"https://genegraph.clinicalgenome.org/r/5b9113ec-aa38-4824-9a8b-6ac3d7c3a732"}},{"id":"https://genegraph.clinicalgenome.org/r/953027aa-9baf-45ba-a5a0-87a359193d92_proband_segregation","type":"FamilyCosegregation","dc:description":"Number of segregations less than required for consideration.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"3","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/953027aa-9baf-45ba-a5a0-87a359193d92","type":"Family","rdfs:label":"3","member":{"id":"https://genegraph.clinicalgenome.org/r/611c3e16-5ccc-44d2-9f55-c93762f17a33","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"3.1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":51,"allele":{"id":"https://genegraph.clinicalgenome.org/r/16eae146-5b54-48b9-ae56-f8962c0949aa"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001028","obo:HP_0012500","obo:HP_0000256","obo:HP_0001249","obo:HP_0008069","obo:HP_0031447","obo:HP_0012032"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/6b26e03f-a51c-4c23-b9be-b5d19e07991c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","allele":{"id":"https://genegraph.clinicalgenome.org/r/16eae146-5b54-48b9-ae56-f8962c0949aa"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0001249","obo:HP_0031447","obo:HP_0001028","obo:HP_0000256","obo:HP_0012032"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/611c3e16-5ccc-44d2-9f55-c93762f17a33"}},{"id":"https://genegraph.clinicalgenome.org/r/a07f5001-b55c-4f0e-aa81-ec9b222a6f2b_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"22","family":{"id":"https://genegraph.clinicalgenome.org/r/a07f5001-b55c-4f0e-aa81-ec9b222a6f2b","type":"Family","rdfs:label":"22","member":{"id":"https://genegraph.clinicalgenome.org/r/827da60e-a275-407c-8ba3-fdb5b921146c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"22.1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"allele":{"id":"https://genegraph.clinicalgenome.org/r/ee47d907-0439-43f1-a309-14e47d17a3d7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.517C>T (p.Arg173Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA000498"}},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0000256","obo:HP_0001249"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/cb233668-6807-4fb5-8d62-ea870d213b21_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","allele":{"id":"https://genegraph.clinicalgenome.org/r/ee47d907-0439-43f1-a309-14e47d17a3d7"},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}}},"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0001249","obo:HP_0000256"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/827da60e-a275-407c-8ba3-fdb5b921146c"}},{"id":"https://genegraph.clinicalgenome.org/r/515e9d0e-573e-4930-bb6d-41ba6564194e_proband_segregation","type":"FamilyCosegregation","dc:description":"Number of segregations less than required for consideration.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"24","estimatedLodScore":0.6,"family":{"id":"https://genegraph.clinicalgenome.org/r/515e9d0e-573e-4930-bb6d-41ba6564194e","type":"Family","rdfs:label":"24","member":{"id":"https://genegraph.clinicalgenome.org/r/18ae7c3f-727e-4883-904f-d83b235f3ae6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","rdfs:label":"24.1","ageType":"AgeAtReport","ageUnit":"Months","ageValue":47,"allele":{"id":"https://genegraph.clinicalgenome.org/r/afe00206-0d01-4bc1-97f7-0849770df593","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.388C>T (p.Arg130Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA000433"}},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001249","obo:HP_0000256"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/b5bd9f26-607b-40b0-bfd2-5c877b055cf2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17526800","allele":{"id":"https://genegraph.clinicalgenome.org/r/afe00206-0d01-4bc1-97f7-0849770df593"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":3,"phenotypes":"obo:HP_0000256","proband":{"id":"https://genegraph.clinicalgenome.org/r/18ae7c3f-727e-4883-904f-d83b235f3ae6"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/6b26e03f-a51c-4c23-b9be-b5d19e07991c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6b26e03f-a51c-4c23-b9be-b5d19e07991c_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/6b26e03f-a51c-4c23-b9be-b5d19e07991c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Variant classified as pathogenic by ClinGen PTEN Expert Panel. Null catalytic activity per Han 2000 (PMID 10866302), Rodriguez-Escudero 2011 (PMID 21828076), dramatic reduction in phosphatase activity per Andres-Pons 2007 (PMID 17942903), Myers 1997 (PMID 9256433).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4bb93db0-5367-4de6-9219-172895eecbd7","type":"EvidenceLine","dc:description":"The proband was heterozygous for the missense variant, Val217Asp, that was absent in the parents. Variant was shown to be de novo without confirmation of maternity and paternity. In the absence of functional evidence, variant is scored 0.5 points.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4bb93db0-5367-4de6-9219-172895eecbd7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28523199","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ed44819-f297-4753-81b1-f06fa4daf5ab","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.650T>A (p.Val217Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA377484783"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5105634f-45c2-4e70-a86a-75a0eaa99812","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5105634f-45c2-4e70-a86a-75a0eaa99812_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26246517","allele":{"id":"https://genegraph.clinicalgenome.org/r/9f361ce9-ff11-4078-a5ae-ad982d8bed95","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.203A>G (p.Tyr68Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10578910"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/5105634f-45c2-4e70-a86a-75a0eaa99812_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional evidence is available from PMIDs: 29785012, 29706350, 19457929","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/69a10554-910a-4aed-b007-930fb746d6bb","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/69a10554-910a-4aed-b007-930fb746d6bb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36082652","allele":{"id":"https://genegraph.clinicalgenome.org/r/afe00206-0d01-4bc1-97f7-0849770df593"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/267e5dff-6197-4982-a1f3-176d2074c5d5","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/267e5dff-6197-4982-a1f3-176d2074c5d5_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ded29e8c-5492-43ed-85fe-e1585f3d6635","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ded29e8c-5492-43ed-85fe-e1585f3d6635_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22595938","allele":{"id":"https://genegraph.clinicalgenome.org/r/e5081835-5c3a-4aa5-9e13-8a85a26da008","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.1003C>T (p.Arg335Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA000245"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/43de9fc9-b373-4521-8f0b-da633411c800","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/43de9fc9-b373-4521-8f0b-da633411c800_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22595938","allele":{"id":"https://genegraph.clinicalgenome.org/r/fedc864c-22b2-4c42-8713-835cc309f640","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.76A>C (p.Thr26Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/234410"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/450e412c-29c3-4438-b453-78b953cdeeb8","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/450e412c-29c3-4438-b453-78b953cdeeb8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26246517","allele":{"id":"https://genegraph.clinicalgenome.org/r/a6e67b05-6300-4898-a8a5-c230512052a6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.87T>A (p.Tyr29Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA377784391"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/b5bd9f26-607b-40b0-bfd2-5c877b055cf2","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b5bd9f26-607b-40b0-bfd2-5c877b055cf2_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/95b9782b-0ce6-4486-8f2e-e971b34db68e","type":"EvidenceLine","dc:description":"Co-segregation with disease in multiple affected family members, with 3 meioses observed.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/95b9782b-0ce6-4486-8f2e-e971b34db68e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22628360","allele":{"id":"https://genegraph.clinicalgenome.org/r/ee47d907-0439-43f1-a309-14e47d17a3d7"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/cb233668-6807-4fb5-8d62-ea870d213b21","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cb233668-6807-4fb5-8d62-ea870d213b21_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0fcd4e51-616e-43b6-9db1-cef478806eca","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0fcd4e51-616e-43b6-9db1-cef478806eca_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/5e234865-4862-493e-92e9-4e3c291959e6","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e234865-4862-493e-92e9-4e3c291959e6_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/5e234865-4862-493e-92e9-4e3c291959e6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Null catalytic activity per Han 2000 (PMID 10866302), Rodriguez-Escudero 2011 (PMID 21828076), dramatic reduction in phosphatase activity per Andres-Pons 2007 (PMID 17942903), Myers 1997 (PMID 9256433).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/630e9d9d-14af-4716-9bda-455f6a0cb8ae","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/630e9d9d-14af-4716-9bda-455f6a0cb8ae_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22595938","allele":{"id":"https://genegraph.clinicalgenome.org/r/148897aa-b108-467a-a8e2-8707d4a073bc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000314.8(PTEN):c.737C>T (p.Pro246Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA000559"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/159c5bce-aafd-44f2-8823-e45074db41f9","type":"EvidenceLine","dc:description":"Did not provide the details about the variants. Only detected blood PTEN protein levels.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/df369030-35cf-423c-9880-b488974971a9","type":"Finding","dc:description":"Study included 17 individuals with nonsense or frameshift variants and found their PTEN protein expression levels to be significantly lower than individuals (N=555) with wild-type/VUS PTEN results. Nonsense or framshift variants are predicted to result in loss of function, which is a mechanism of disease for PTEN.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23066114","rdfs:label":"PTEN protein expression","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/52fc9e2f-1573-4d77-8eda-b30d35b31041","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4407c6c7-6e20-46b7-bc6a-db7bb73ad907","type":"Finding","dc:description":"This paper detected loss-of-function variants and/or loss of heterozygosity at the PTEN/MMAC1 locus in multiple tumor and tumor cell line specimens. The tissues with mutations/LOH identified correspond to the tissues at increased tumor risk (breast, thyroid, renal, colon, skin, brain) in individuals with PTEN Hamartoma Tumor syndrome.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9393738","rdfs:label":"Tumor/cell line analysis","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fa69b901-2966-4d59-95b1-54421aa83174","type":"EvidenceLine","dc:description":"This study found loss or mutation of PTEN in 13 out of 17 glioma cell lines and linked function of this gene to suppression of glioma cell growth.  This is one of the first studies proving PTEN's role as a tumor suppressor. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a7cb2d21-69a6-4bed-a316-30aac8d72920","type":"Finding","dc:description":"The data in this paper strongly suggest that PTEN is a protein phosphatase that exhibits functional and specific growth-suppressing activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9356475","rdfs:label":"Glioma cell line growth suppression","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d0db078f-db3b-4c6b-a0fe-fe660a66957e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ade9478-d156-4ee2-88b5-fe37a0bda39f","type":"Finding","dc:description":"This study was performed in a mouse model harboring homozygous knockout of exons 3-5, which comprise much of the protein including the entire phosphatase core.  This is a key study connecting PTEN's role as a tumor suppressor to its' canonical phosphatase activity. Overgrowth and tumorigenesis are the hallmark features of PHTS.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9393738","rdfs:label":"Negative Regulation of PKB/Akt-Dependent Cell Survival","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/066063d1-d702-4855-9ef9-b578560dbf19","type":"EvidenceLine","dc:description":"Lipid phosphatase activity is a canonical PTEN function; disruption of this process is one mechanism by which tumor formation occurs as a component of PHTS. This assay is considered the \"gold standard\" for this gene and was performed with adequate replicates and positive/negative controls.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bbd75cce-394d-425a-a89b-733c45561f38","type":"FunctionalAlteration","dc:description":"Mutations in P-loop [A121V, I122L, I122V, H123Y, C124N, K125L, K125M, K125R, A126D, A126G, G127N, K128R, K128T, G129D, G129A, R130A, R130K, T131I, T131L and T131S]. A group of mutations (H123Y, C124N, A126D, G127N, K128T, G129D, R130A, R130K, T131I and T131L) fully abrogated the PIP3 phosphatase activity of PTEN in yeast.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21828076","rdfs:label":"Yeast phosphatase activity"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5096d6ea-2721-4cbe-babe-168c64c10ccc","type":"EvidenceLine","dc:description":"Study grouped disease-associated variants, but did not specify which variants were included.  However, data were statistically significant and N of patient (N=24) and control (N=244) samples studied impressive.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62cdd579-5150-4b6c-b947-48c596021611","type":"FunctionalAlteration","dc:description":"Study found decreased PTEN expression (p=0.01) and increased pAKT expression (p=0.03) in patient cells.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21194675","rdfs:label":"PTEN/pAKT expression in patient LCLs"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/63190903-b690-4dfe-a7ed-6324f951e7d7","type":"EvidenceLine","dc:description":"M3M4 mutant has a combination of 5 separate missense variants.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/52de0154-edae-4195-892b-88177c569621","type":"Finding","dc:description":"Heterozygous mutant mice demonstrate noticeable and significant macrocephaly as a result of megancephaly (overgrowth of brain tisue).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21343951","rdfs:label":"M3M4 mouse model cerebral overgrowth","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/002932dd-17d0-4e78-bde5-dde9e7824681","type":"EvidenceLine","dc:description":"This model is homozygous; living affected persons are heterozygous.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c0bc5a6-68b1-4fa7-8b54-e33ce94aeadc","type":"Finding","dc:description":"Mouse homozygous for deletion was embryonic lethal, consistent with lack of reports of individuals with germline biallelic PTEN pathogenic variants.  Mouse embryos demonstrated increased cell proliferation and caudal and cephalic overgrowth, consistent with human phenotype.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9778245","rdfs:label":"Homozygous mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4681de8a-cc41-4787-90af-948425e2dab2","type":"EvidenceLine","dc:description":"The mouse model shows autoimmune features that are observed in human individuals with PTEN variants. This information is a supplement to the PTEN model evidence and is therefore scored reduced points. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4ae7e48b-00bc-420a-997c-36627c11a7ea","type":"Finding","dc:description":"Pten+/- mutants develop a lethal polyclonal autoimmune disorder with features reminiscent of those observed in Fas-deficient mutants. Complete disruption of Pten in the mouse results in early embryonic lethality. Pten+/- mice display hyperplastic-dysplastic features as well as high tumor incidence.\n44/45 of Pten+/- females (C57BL6/129Sv background) developed, between 4 and 5 months of age, a severe lymphoadenopathy affecting mainly the submandibular, axillary, and inguinal lymph nodal stations. The mice died, most likely of renal failure, before they were 1 year old. 20/24 male mutants developed less severe lymph node hyperplasia by 8 months of age and surviving up to at least 15 months.\nOverall, mice showed autoimmune features including enlarged spleen, hyperplastic lymph nodes, congested organs with inflammatory infiltrates, and kidneys that showed proliferation of mesangial cells and increased extracellular matrix in the glomeruli, accompanied by vacuolization and dilation of proximal tubules, with the presence of proteinaceous material in the lumen.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10497129","rdfs:label":"Di Cristofano_Pten+/- Mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":11877,"specifiedBy":"GeneValidityCriteria10","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/evaXVkhGl4o","type":"GeneValidityProposition","disease":"obo:MONDO_0017623","gene":"hgnc:9588","modeOfInheritance":"obo:HP_0000006"},"version":"2.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_2e9e89c0-8d1b-4276-bd6f-90c7b7190ffb-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}